News from harbour biomed A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 13, 2021, 02:55 ET Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting

Harbour BioMed ("HBM"; HKEX: 02142.HK), a global clinical-stage biopharmaceutical company, presents its newly discovered fully human anti-B7H7...

Mar 21, 2021, 20:30 ET Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China

Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the first patient in its open Phase I clinical study of HBM4003 for Chinese patients ...

Mar 11, 2021, 20:00 ET Harbour BioMed Announces Dosing of First Patient in Tanfanercept Phase III Clinical Trial

Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the first patient in the Phase III clinical trial of its new global investigational...

Feb 25, 2021, 21:16 ET Harbour BioMed Announces NMPA Approval of IND for Combination Therapy of Next Gen Anti-CTLA-4 Antibody for Treatment of NSCLC and Solid Tumors

Harbour BioMed (HBM) (HKEX: 02142) today announced that the China National Medical Products Administration (NMPA) has approved its Investigational...

Jan 27, 2021, 23:40 ET Harbour BioMed's Batoclimab (HBM9161) Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients with Myasthenia Gravis

Harbour BioMed (HBM) (HKEX: 02142.HK), announced today that China Center for Drug Evaluation (CDE) has granted Breakthrough Therapy designation to...

Dec 14, 2020, 19:00 ET Harbour BioMed and Utrecht University Announce License Agreement with AbbVie and Initiation of COVID-19 Antibody Clinical Trials

Harbour BioMed (HBM)(HKEX:02142), and Utrecht University (UU) today announced that they licensed to AbbVie their fully human, SARS-CoV-2 neutralizing ...

Nov 16, 2020, 07:13 ET Harbour BioMed Will Present Results From Its Phase II Clinical Trial with Tanfanercept (HBM9036) in Patients with Moderate-to-Severe Dry Eye Disease in China at the 25th Congress of Chinese Ophthalmological Society

Harbour BioMed (HBM), a global, clinical-stage, bio-pharmaceutical company today announced that the company will present the phase II clinical trial...

Sep 30, 2020, 08:59 ET Harbour BioMed Announces Dosing of First Patients in Two Phase II Clinical Studies of Batoclimab (HBM9161) for the Treatment of Myasthenia Gravis and Immune Thrombocytopenia

Harbour BioMed (HBM), a global, clinical-stage, bio-pharmaceutical company announced today the dosing of the first patient in two separate Phase II...

Sep 21, 2020, 08:07 ET Harbour BioMed Announces Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors

Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company announced approval of two Investigational New Drug (IND)...

Sep 11, 2020, 09:13 ET Harbour BioMed and Hualan Genetic Announced Collaboration to Develop Multiple Innovative Antibody Programs

Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company today announced a strategic partnership agreement with Hualan...

Sep 02, 2020, 00:03 ET Harbour BioMed Presented Its Newly Discovered Anti-Human CCR8 Novel Monoclonal Antibodies at the 16th PEGS Boston 2020

Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company, presented its newly discovered novel anti-human CCR8 mAbs...

Aug 31, 2020, 09:30 ET Harbour BioMed Will Present Its New Platform HBICE (Heavy chain only antibody (HCAb) Based Immune Cell Engager) at 16th PEGS Boston Summit

Harbour BioMed, a global, clinical-stage, innovative biopharmaceutical company, today announced that it presented its newly developed HBICETM (HCAb...

Aug 24, 2020, 07:00 ET Harbour BioMed Signs Strategic Collaboration Agreement with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases

Harbour BioMed (HBM), a global clinical-stage biopharmaceutical company today announced that it has entered into a strategic collaboration with Vir...

Aug 21, 2020, 09:28 ET Harbour BioMed Presented Its Newly Discovered BCMA x CD3 Bispecific Antibody at Cell Engager Summit 2020

Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company, presented its newly discovered Bispecific Antibody - BCMA x CD3 ...

Aug 19, 2020, 07:44 ET Harbour BioMed, Utrecht University, Erasmus Medical Center, Viroclinics-DDL and Kiadis Pharma Announce Collaboration to Develop Monoclonal Antibody, Natural Killer Cell Combination Approach to Treating COVID-19

Harbour BioMed (HBM), and its partners Utrecht University and Erasmus Medical Center, today announced a new research collaboration with...

Jul 30, 2020, 20:32 ET Harbour BioMed Announces Strategic Partnership with Viva Biotech to Collaborate on Incubating Innovative Biotech Start-ups

Harbour BioMed (HBM), a global clinical stage biopharmaceutical company and Viva Biotech (Shanghai) Ltd. ("Viva Biotech"), a world-leading...

Jul 15, 2020, 18:00 ET Harbour BioMed Presented Pre-Clinical Data on A Fully Human Anti-CD73 Antibody at AACR Virtual Annual Meeting

Harbour BioMed (HBM), a global clinical stage biopharmaceutical company, today announced that the Company presented preclinical data from a fully...

Jun 11, 2020, 06:00 ET Harbour BioMed Appoints Dr. Jon Wigginton to its Scientific Advisory Board

Harbour BioMed (HBM) announced today the appointment of Dr. Jon Wigginton M.D., to the company's scientific advisory board (SAB). Dr. Wigginton is a...

Apr 21, 2020, 22:35 ET Harbour BioMed Announces First Patient Dosing of Phase 1b/2a Study of Anti-FcRn Batoclimab for Treating Neuromyelitis Optica Spectrum Disorder

Harbour BioMed (HBM) today announced first patient dosing in a Phase 1b/2a study of its anti-FcRn antibody, batoclimab (HBM9161), for the treatment...

May 05, 2019, 22:33 ET Harbour BioMed and Chia Tai Tianqing Pharmaceutical Group Ltd. Announce Strategic Alliance to Discover, Develop and Commercialize Innovative Biologics

Harbour BioMed and Chia Tai Tianqing Pharmaceutical Group Ltd. (CTTQ) today announced they are entering into a strategic alliance to discover,...